Literature DB >> 17644861

Osteoporosis: prevention and treatment in anorexia nervosa.

A Wolfert1, P S Mehler.   

Abstract

One of the most serious and potentially permanently disabling medical complications of anorexia nervosa is osteoporosis, which greatly increases the long-term risk of bone fractures. The decreased bone density in patients with anorexia nervosa (AN) is due to the many effects on bone metabolism of amenorrhea, reduced levels of insulin growth factor-1 (IGF-1), high cortisol levels and weight loss. Although estrogen replacement therapy is clearly efficacious in preventing postmenopausal osteoporosis, its efficacy in AN is uncertain. Clinicians caring for patients with AN need to be aware of this because, despite such therapy, there may be an inexorable decline in bone mineral density in what is a relatively young group of patients. AN frequently has its onset during adolescence, when peak bone mass is normally reached, and an anorectic episode in youth may permanently impair skeletal integrity and lead to debilitating fractures and pain. It is important to recognise this formidable risk, counsel AN patients about the longterm and possibly permanent sequelae of low body weight, use densitometry to screen for bone loss and treat it accordingly. The most effective treatment is still early weight restoration and the resumption of menses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 17644861     DOI: 10.1007/bf03354433

Source DB:  PubMed          Journal:  Eat Weight Disord        ISSN: 1124-4909            Impact factor:   4.652


  75 in total

1.  Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study.

Authors:  T Lloyd; D S Taylor; H M Lin; A E Matthews; D F Eggli; R S Legro
Journal:  Fertil Steril       Date:  2000-10       Impact factor: 7.329

2.  Exercise-associated amenorrhea, low bone density, and estrogen replacement therapy.

Authors:  D C Cumming
Journal:  Arch Intern Med       Date:  1996-10-28

3.  Leptin levels in restricting and purging anorectics.

Authors:  P S Mehler; R H Eckel; W T Donahoo
Journal:  Int J Eat Disord       Date:  1999-09       Impact factor: 4.861

4.  Resumption of menses in anorexia nervosa.

Authors:  N H Golden; M S Jacobson; J Schebendach; M V Solanto; S M Hertz; I R Shenker
Journal:  Arch Pediatr Adolesc Med       Date:  1997-01

Review 5.  Diagnosis and care of patients with anorexia nervosa in primary care settings.

Authors:  P S Mehler
Journal:  Ann Intern Med       Date:  2001-06-05       Impact factor: 25.391

6.  Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa.

Authors:  S Grinspoon; E Thomas; S Pitts; E Gross; D Mickley; K Miller; D Herzog; A Klibanski
Journal:  Ann Intern Med       Date:  2000-11-21       Impact factor: 25.391

Review 7.  Mechanisms of glucocorticoid action in bone cells.

Authors:  A M Delany; Y Dong; E Canalis
Journal:  J Cell Biochem       Date:  1994-11       Impact factor: 4.429

8.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W Browner; J Cauley; K Ensrud; H K Genant; L Palermo; J Scott; T M Vogt
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

9.  Amenorrhea in anorexia nervosa. Neuroendocrine control of hypothalamic dysfunction.

Authors:  N H Golden; I R Shenker
Journal:  Int J Eat Disord       Date:  1994-07       Impact factor: 4.861

Review 10.  Pathophysiology of osteoporosis.

Authors:  R P Heaney
Journal:  Endocrinol Metab Clin North Am       Date:  1998-06       Impact factor: 4.741

View more
  2 in total

Review 1.  Biology without walls: the novel endocrinology of bone.

Authors:  Gerard Karsenty; Franck Oury
Journal:  Annu Rev Physiol       Date:  2011-11-07       Impact factor: 22.163

2.  Seven years' experience with etidronate in a woman with anorexia nervosa and vertebral fractures.

Authors:  Jun Iwamoto; Yoshihiro Sato; Mitsuyoshi Uzawa; Tsuyoshi Takeda; Hideo Matsumoto
Journal:  Ther Clin Risk Manag       Date:  2011-07-05       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.